In the present study, using large cohorts of pancreatic cancer patients derived from TCGA datasets and Gene Expression Omnibus (GEO) datasets, the prognostic significance of KRAS mutation, TP53 mutation, CDKN2A deletion and SMAD alteration was determined. This evidence concerns the gene TP53 and familial pancreatic carcinoma.